SCH 900353--ERK Inhibitor
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $32,951 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $32,951 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK8353 formerly known as SCH 900353 in Subjects with Advanced Solid Tumors Protocol No. 001 formerly known as P06203 | Merck Sharp & Dohme Corporation | $32,951 | 0 |
Top Doctors Receiving Payments for SCH 900353--ERK Inhibitor
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $32,951 | 1 |
Manufacturing Companies
- Merck Sharp & Dohme Corporation $32,951
Product Information
- Type Drug
- Total Payments $32,951
- Total Doctors 0
- Transactions 1
About SCH 900353--ERK Inhibitor
SCH 900353--ERK Inhibitor is a drug associated with $32,951 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2018. In 2018, $32,951 was paid across 1 transactions to 0 doctors.
The most common payment nature for SCH 900353--ERK Inhibitor is "Unspecified" ($32,951, 100.0% of total).
SCH 900353--ERK Inhibitor is associated with 1 research study, including "A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK8353 formerly known as SCH 900353 in Subjects with Advanced Solid Tumors Protocol No. 001 formerly known as P06203" ($32,951).